• Recruiting

NCT03428373: Phase 2: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)

NCT03428373: Phase 2: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)

Rivaroxaban or Aspirin As Thromboprophylaxis

NCT03428373: Phase 2: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)


The intended study is designed as a a phase IV pragmatic multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs. Rivaroxaban in newly diagnosed or relapsed and refractory multiple myeloma patients treated with Lenalidomide Dexamethasone (Len-Dex) combination therapy. The pilot feasibility study was conducted in preparation for this randomized controlled trial designed to assess the effect of an intervention.


Sponsor

Lawson Health Research Institute


Collaborators

The Ottawa Hospital

Dalhousie University

Niagara Health System

Hamilton Health Sciences Corporation

 

ClinicalTrials.gov Identifier: NCT03428373

Official Title: Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial

First Posted : February 9, 2018

Click here to see details on ClinicalTrials.gov

 

Drug: Rivaroxaban

Drug: ASA

 

Locations

Canada, Ontario



Tags:

Posts Archive